• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

托芬那酸:一种tau蛋白修饰剂及其在认知和tau蛋白病中的作用。

Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.

作者信息

Chang Joanna K, Leso Allison, Subaiea Gehad M, Lahouel Asma, Masoud Anwar, Mushtaq Foqia, Deeb Reem, Eid Aseel, Dash Miriam, Bihaqi Syed W, Zawia Nasser H

机构信息

Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, United States.

Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, United States.

出版信息

Curr Alzheimer Res. 2018;15(7):655-663. doi: 10.2174/1567205015666180119104036.

DOI:10.2174/1567205015666180119104036
PMID:29357795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7092365/
Abstract

BACKGROUND

Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.

OBJECTIVE

In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).

METHODS

Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.

RESULTS

Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.

CONCLUSION

TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD.

摘要

背景

缠结是过度磷酸化tau蛋白的沉积物,在多种被称为tau蛋白病的神经退行性疾病中均可发现,其中阿尔茨海默病(AD)最为常见。tau蛋白病的临床特征为痴呆,并具有由tau蛋白聚集体构成的共同皮质病变。

目的

在本研究中,我们探讨了托芬那酸(TA)在携带人类tau基因(hTau)的转基因动物模型中改善疾病进程的治疗潜力。

方法

采用行为测试、蛋白质印迹法和免疫组织化学分析来证明TA的疗效。

结果

TA治疗改善了年轻和老年hTau小鼠的空间学习缺陷和记忆障碍。对hTau蛋白的蛋白质印迹分析显示,给予TA后,总tau蛋白以及tau蛋白位点特异性过度磷酸化均减少。对磷酸化tau蛋白的免疫组织化学分析显示,接受TA治疗的动物额叶皮质、海马体和纹状体中的染色减少。

结论

TA有潜力作为一种疾病修饰剂用于治疗包括AD在内的tau蛋白病。

相似文献

1
Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.托芬那酸:一种tau蛋白修饰剂及其在认知和tau蛋白病中的作用。
Curr Alzheimer Res. 2018;15(7):655-663. doi: 10.2174/1567205015666180119104036.
2
Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.新型泌乳素释放肽类似物改善tau 病小鼠模型的记忆障碍并减轻 Tau 蛋白过度磷酸化
J Alzheimers Dis. 2018;62(4):1725-1736. doi: 10.3233/JAD-171041.
3
Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.替西罗莫司通过靶向tau蛋白过度磷酸化和自噬清除在体外和体内减轻tau蛋白病。
Neuropharmacology. 2014 Oct;85:121-30. doi: 10.1016/j.neuropharm.2014.05.032. Epub 2014 May 29.
4
A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.一种由天然启动子驱动表达双突变tau的新型转基因小鼠表现出tau蛋白病特征。
Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.
5
Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.小鼠tau蛋白病模型中CA1神经元的早期耗竭和晚期神经变性。
Brain Res. 2017 Jun 15;1665:22-35. doi: 10.1016/j.brainres.2017.04.002. Epub 2017 Apr 11.
6
Dihydroartemisinin promotes tau O-GlcNAcylation and improves cognitive function in hTau transgenic mice.双氢青蒿素促进 tau O-GlcNAcylation 并改善 hTau 转基因小鼠的认知功能。
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Dec 20;135:111105. doi: 10.1016/j.pnpbp.2024.111105. Epub 2024 Jul 23.
7
Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy.白藜芦醇挽救了tau 病模型中小鼠 tau 诱导的认知缺陷和神经病理学。
Curr Alzheimer Res. 2019;16(8):710-722. doi: 10.2174/1567205016666190801153751.
8
Dihydroartemisinin Induces O-GlcNAcylation and Improves Cognitive Function in a Mouse Model of Tauopathy.双氢青蒿素诱导 O-GlcNAcylation 并改善 Tauopathy 小鼠模型的认知功能。
J Alzheimers Dis. 2021;84(1):239-248. doi: 10.3233/JAD-210643.
9
The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.5-脂氧合酶在tau 病理学、突触完整性和tau 病小鼠模型认知中的直接作用。
Transl Psychiatry. 2017 Dec 18;7(12):1288. doi: 10.1038/s41398-017-0017-2.
10
Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.托芬那酸可降低tau蛋白和细胞周期蛋白依赖性激酶5(CDK5)水平:对痴呆症和tau蛋白病的影响。
J Neurochem. 2015 Apr;133(2):266-72. doi: 10.1111/jnc.12960. Epub 2014 Oct 18.

引用本文的文献

1
Natural products against tau hyperphosphorylation-induced aggregates: Potential therapies for Alzheimer's disease.针对tau蛋白过度磷酸化诱导的聚集体的天然产物:阿尔茨海默病的潜在疗法。
Arch Pharm (Weinheim). 2025 Jan;358(1):e2400721. doi: 10.1002/ardp.202400721.
2
Photolysis of tolfenamic acid in aqueous and organic solvents: a kinetic study.托芬那酸在水性和有机溶剂中的光解:一项动力学研究。
RSC Adv. 2024 Jul 8;14(30):21383-21397. doi: 10.1039/d4ra01369g. eCollection 2024 Jul 5.
3
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.治疗进行性核上性麻痹的药物疗法:一项叙述性综述。
Neurol Ther. 2024 Aug;13(4):975-1013. doi: 10.1007/s40120-024-00614-9. Epub 2024 May 14.
4
Tolfenamic Acid Derivatives: A New Class of Transcriptional Modulators with Potential Therapeutic Applications for Alzheimer's Disease and Related Disorders.托芬那酸衍生物:一类新型转录调节剂,有望用于治疗阿尔茨海默病及相关疾病。
Int J Mol Sci. 2023 Oct 16;24(20):15216. doi: 10.3390/ijms242015216.
5
Therapeutic strategies for tauopathies and drug repurposing as a potential approach.tau 病的治疗策略和药物再利用作为一种潜在方法。
Biochem Pharmacol. 2022 Apr;198:114979. doi: 10.1016/j.bcp.2022.114979. Epub 2022 Feb 24.
6
Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.帕金森综合征的新型疗法——近期进展与未来展望
Front Mol Neurosci. 2021 Aug 26;14:720220. doi: 10.3389/fnmol.2021.720220. eCollection 2021.
7
Fenamates as Potential Therapeutics for Neurodegenerative Disorders.非甾体类抗炎药类作为神经退行性疾病的潜在治疗药物。
Cells. 2021 Mar 22;10(3):702. doi: 10.3390/cells10030702.
8
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration.用于额颞叶痴呆的实验性疾病修饰药物。
J Exp Pharmacol. 2021 Mar 24;13:359-376. doi: 10.2147/JEP.S262352. eCollection 2021.
9
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations.药物重新定位作为与OPA1突变相关神经退行性疾病的治疗策略。
Hum Mol Genet. 2021 Jan 21;29(22):3631-3645. doi: 10.1093/hmg/ddaa244.
10
Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.托法替布酸抑制阿尔茨海默病模型中 GSK-3β 和 PP2A 介导的 tau 过度磷酸化。
J Physiol Sci. 2020 Jun 9;70(1):29. doi: 10.1186/s12576-020-00757-y.

本文引用的文献

1
Developmental exposure to lead (Pb) alters the expression of the human tau gene and its products in a transgenic animal model.在转基因动物模型中,发育过程中接触铅(Pb)会改变人类tau基因及其产物的表达。
Neurotoxicology. 2016 Jul;55:154-159. doi: 10.1016/j.neuro.2016.06.001. Epub 2016 Jun 9.
2
The amyloid hypothesis of Alzheimer's disease at 25 years.阿尔茨海默病淀粉样蛋白假说25年回顾
EMBO Mol Med. 2016 Jun 1;8(6):595-608. doi: 10.15252/emmm.201606210. Print 2016 Jun.
3
Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.托芬那酸可降低tau蛋白和细胞周期蛋白依赖性激酶5(CDK5)水平:对痴呆症和tau蛋白病的影响。
J Neurochem. 2015 Apr;133(2):266-72. doi: 10.1111/jnc.12960. Epub 2014 Oct 18.
4
Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid.托芬那酸可减少β-淀粉样蛋白沉积并减轻记忆缺陷。
J Alzheimers Dis. 2015;43(2):425-33. doi: 10.3233/JAD-132726.
5
Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.托芬那酸下调β-分泌酶1(BACE1)并预防铅诱导的阿尔茨海默病相关生物标志物上调。
Neuropharmacology. 2014 Apr;79:596-602. doi: 10.1016/j.neuropharm.2014.01.009. Epub 2014 Jan 21.
6
Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.托芬那酸短期治疗可改善阿尔茨海默病小鼠的认知功能。
Neurobiol Aging. 2013 Oct;34(10):2421-30. doi: 10.1016/j.neurobiolaging.2013.04.002. Epub 2013 Apr 30.
7
Pathogenesis of the tauopathies.tau 病的发病机制。
J Mol Neurosci. 2011 Nov;45(3):425-31. doi: 10.1007/s12031-011-9593-4. Epub 2011 Jul 23.
8
Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study.两种阿尔茨海默病模型小鼠的嗅觉和视空间学习记忆能力——一项纵向研究。
PLoS One. 2011 May 5;6(5):e19567. doi: 10.1371/journal.pone.0019567.
9
Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway.托芬那酸通过转录途径中断β-淀粉样前体蛋白的从头合成并降低淀粉样β。
Curr Alzheimer Res. 2011 Jun;8(4):385-92. doi: 10.2174/156720511795745285.
10
The acetylation of tau inhibits its function and promotes pathological tau aggregation.tau 蛋白乙酰化会抑制其功能,并促进病理性 tau 聚集。
Nat Commun. 2011;2:252. doi: 10.1038/ncomms1255.